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SUMMARY 
 
Implementing the findings of research to change the behaviour of health care professionals 
has become an increasingly prominent issue.  However, designing valid studies to evaluate 
different methods of achieving changes requires considerable care and there are a number of 
pitfalls evident from published previous work.  The various steps in the development of an 
implementation method and issues arising are explored in this text.  Aspects include 
conceptualisation, essential background work, a structured development process, the relative 
merits of randomised and non-equivalent group designs, the unit of analysis, the role of 
multi-level models, block designs, economic analysis, and the content or message to be 
disseminated.  An ongoing, large, randomised trial of educational outreach visits by trained 
pharmacists is used to illustrate some of the issues. 
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INTRODUCTION 
 
The recent National Health Service White paper places great emphasis on quality assurance, 
one facet being clinicians’ awareness and application of the best evidence available for the 
treatment of patients. [1]  However, it is apparent that important findings from large 
randomised trials and systematic overviews in areas such as the treatment of heart failure, 
[2,3] antiplatelet therapy [4,5] and thrombolytic therapy [6,7] do not translate automatically 
into practice, [8-10].  The process of trying to implement research findings raises a number of 
difficulties. [11,12]  As David Eddy has commented, while the medical profession has placed 
a high value on developing the basic science of medicine, it has not emphasized the process 
by which that science is translated into practice. [12] 
 
The English NHS has recognised explicitly the need to focus effort on the implementation 
issue [13] and has recently commenced a programme of research focusing largely on 
randomised and quasi-experimental studies of interventions to change practice. [14]  This text 
explores the design and analysis issues for methods intended to promote appropriate 
behavioural change.  Some of the material is technical and assumes knowledge of the design 
of studies to evaluate health care treatments.  Building from this starting point, the intention 
is to aid clarity of thought on the part of those involved in designing or evaluating 
implementation research.  
 
First, the importance of undertaking initial qualitative work is discussed.   Second, we review 
the characteristics of experimental and quasi-experimental studies and the interpretation of 
their results.   Third, we consider issues that impact upon the choice of the unit of analysis in 
evaluations of interventions intended to change practice. Fourth, we explore block study 
designs as a mechanism for dealing with problems of variation and bias peculiar to 
implementation studies. Finally, we examine the design issues for the inclusion of economics. 
 
ASKING THE RIGHT QUESTIONS 
 
Doing the developmental work first 
It is fundamental to any research to begin by asking the right questions and then choosing the 
right methods to answer them.  This may seem obvious, but it is possible to identify 
quantitative research that might have been considered unnecessary or poorly focused had 
qualitative work been used to judge whether the hypotheses under test were sensible.   For 
example, the perceived need for information by primary care physicians was identified in one 
small trial assessing intermediate outcome measures. [15] 
 Its provision was subsequently 
evaluated within a larger randomised trial with objective measurement of patient and health 
professional outcomes. [16]  The outcome of the larger trial was that the simple provision of 
information to doctors did not appear to bring substantial direct benefits to patients, a 
conclusion confirmed in a subsequent systematic review of this question. [10]  In an 
observational study, Covell and colleagues [17] identified that the perceived need for better 
information among office-based practitioners was not reflected in their behaviour.  Although 
doctors perceived that they answered questions arising from their work through traditional 
information sources such as textbooks and journal articles, they actually resolved such issues 
through consultation with colleagues.  Thus, it was, a priori, unlikely that the provision of Evaluating Change in Professional Behaviour  2 
information by itself would be effective.  In this instance, the quantitative evaluation was ill-
focused when considered in the light of the relevant qualitative research. 
 
A sequence of questions 
Historically, most randomised trials in the medical field have been conducted with drugs, 
[18] reflecting both the dominance of this form of treatment in modern western health care 
systems and the financial and regulatory state of the pharmaceutical industry.   Those 
attempting to develop and evaluate interventions to increase the uptake of research findings 
might usefully reflect on the processes in the development of drugs.   Research and 
development in the pharmaceutical field commences a very long way from patients, and also 
a long way from clinical experiments, with substantial pre-clinical work aimed at developing 
and describing the attributes of new chemical entities.  Having sorted out how such entities 
behave in test tubes and animals, their action is then examined in healthy volunteers, and 
further evaluated in dose ranging studies. Only eventually are double blind randomised trials 
conducted in groups of diseased individuals. [18]  Stages of pharmaceutical development and 
corresponding stages in the development of implementation interventions are described in 
Table 1.  All the diverse and extensive pre-clinical work has been lumped together and called 
‘Phase 0’.  In the context of the development of interventions intended to influence practice, 
this important stage should include qualitative work to describe and develop an 
understanding of the effects of an implementation approach. 
 
Interventions aiming to introduce research findings to practice, such as computerised decision 
support systems or audit and feedback, require careful development, although most have not 
been through such a development process.  Educational outreach (academic detailing) aiming 
to change prescribing practice is probably the exception, with substantial development of the 
theory and practice of the approach [19] followed ultimately by the evaluation of its 
efficiency in different health systems. [20]  Where interventions are not well established and 
described, investigators risk evaluating the ‘wrong kind’ of audit and feedback or reminder 
system.   Evaluative trials of inadequately developed and understood implementation 
interventions are premature. 
 
Explanatory or pragmatic design? 
An explanatory design aims to increase understanding of the intervention under study, while 
a pragmatic design addresses the size of effect in regular practice.  These different aims have 
important implications for design and analysis. The distinction can also be used to help 
crystallise the purpose of an evaluative trial beyond the ill-specified wish to ‘test out’ the 
treatments of interest, as the two types of experiment have conflicting strengths.  
 
Consistent with the natural sequence of development shown in Table 1, it is important to 
establish that an intervention can work and to gain an understanding of the way it works in 
studies with high construct validity before attempting to evaluate whether it can achieve this 
potential in the real world. CHE Discussion Paper 171  3
Table 1: Phases of clinical trials and proposed comparable phases for implementation evaluations. 
Phase  Drug Trial  Implementation Method 
    
Phase 0   Premedical  research containing many 
stages, including studies in vitro and in 
animals, aiming to describe the action of a 
drug in different (artificial) circumstances. 
Developing new ideas and using qualitative 
research to examine their effects (e.g. developing 
and qualitatively evaluating a computer decision 
support system) 
    
Phase  1  Studies in healthy volunteers, aiming to 
establish safety rather than efficacy of a 
drug. 
Testing the applicability of an intervention in 
artificial but demanding circumstances (e.g. 
testing a computerised decision support system 
with a classroom of computer science students for 
a day). 
    
Phase  2  Small-scale investigations of treatment 
efficacy in diseased individuals, including 
dose ranging, often aiming to screen out 
chemical entities not likely to be clinically 
useful. 
Examining the feasibility of an implementation 
intervention in practice (e.g. assessing the 
potential of a computerised decision support 
system in clinical practice in terms of 
comprehension of prompts and 
reaction/satisfaction of GPs). 
    
Phase 3  Comparison with current standard treatment 
in large-scale rigorous experimental studies 
in diseased individuals. 
Large-scale trials examining the effectiveness of 
an intervention in controlled experimental 
situations (e.g. testing whether the addition of 
computerised decision support has the desired 
effect on practice against mailed information 
alone). 
    
Phase 4  Studies of the use of a drug in established 
practice (post-marketing surveillance/ 
marketing).   Focus on rare side effects and 
potential impact of drug on practice. 
Establishing the effectiveness and efficiency of 
implementation techniques in real world settings  
(e.g. assessing whether widespread 
implementation of promising computerised 
decision support systems has had the desired 
impact upon practice).    
 
For example, consider the design of a trial to evaluate a computer prompt system providing 
treatment guidance for a certain clinical condition. In addition, suppose the guidance to be 
provided is generally available in the clinical literature.  A pragmatically designed trial would 
use a real-world comparison of no formal intervention (clinicians may or may not be aware of 
the literature).  The computer hardware and software would be provided and operated under 
‘normal’ conditions (through a market provider) and no incentives would be offered to 
clinicians to participate (unless these are present under normal service conditions).  An 
explanatory design would feature ‘equalised’ conditions: the control group would all be 
presented with the guidance on paper, the computer prompt system would be provided and 
monitored by the trialists, and incentives may be provided to ensure compliance with the 
protocol.  Both designs explore the extent to which intervention changes behaviour, although 
their findings relate to real world and optimised settings.   
 
The pragmatic design, while clearly more applicable to decision-makers attempting to set 
policy, is vulnerable to a number of confounding influences.  A negative pragmatic trial 
result may reflect the fact that the computer prompt system was inadequately designed, that 
the computer supplier particular to the trial provided inadequate service support, or that the Evaluating Change in Professional Behaviour  4 
clinicians simply ignored the prompts.  A positive result could include some behavioural 
modification through improving participants’ awareness of the main study outcomes; in other 
words, it may not be specific to computerised decision support.  There is seldom an absolute 
dichotomy between ‘pragmatic’ and ‘explanatory’ but in practice a continuum and these 
issues should be addressed at the design stage.  For example, where distribution of 
educational materials is the norm, there may be no difference between explanatory and 
pragmatic design with respect to the choice of the control intervention.  
 
Experimental and quasi-experimental studies 
There are two main forms of experimental designs that may provide valid estimates of the 
effect of interventions - randomised trials and non-equivalent group designs. [21]  In 
randomised trials, subjects are allocated by chance to either treatment or control groups, and 
so bias is distributed between the groups by chance.   In other words, treatment and control 
groups may be considered equivalent, apart from the play of chance.   Non-equivalent group 
study designs allocate subjects without random allocation, and thus differences between the 
groups may reflect systematic biases.    
 
Advantages of randomisation 
Randomised trials are rightly regarded as the most valid means of providing a quantitative 
estimate of the effectiveness of health care interventions.  Randomisation plays a central role 
in ensuring that any extraneous factors (both known and unknown) have an equal chance of 
affecting each treatment group.  However, it does not ensure that each treatment group will 
be comparable, as allocation depends upon the play of chance.   Results are also expected to 
differ according to chance but the process of randomisation ensures that we have a valid 
estimate of the expected size of this variation (through the estimate of experimental error).  
Thus randomisation can be said to ensure the validity of the statistical analysis.  In situations 
where randomisation is practical, there seems no good reason for omitting it.  Unfortunately, 
after the randomisation has been carried out, the groups have an opportunity to diverge, 
simply as a consequence of being labelled differently, rather than as a result of a specific 
treatment effect.  In drug trials, this problem is addressed by making them double-blind 
which, if done successfully, should be a complete answer.  For professional behaviour-
change trials, blinding is not an option and labelling effects need to be addressed in a 
different way. 
 
Non-equivalent group design studies 
In certain circumstances randomisation is not possible, such as national guideline 
implementation programmes or mass media campaigns.  Although potentially useful in these 
circumstances, non-equivalent group designs require more careful interpretation than 
randomised studies.   There are three main potential biases that may affect such studies.   
First, there may be scaling differences in which apparent differences in effect sizes between 
groups over time are in fact associated with the instrument of measurement rather than real 
differences in effect.   Second, it may be that different groups are at different stages in a 
common maturational process, and thus respond to interventions in ways that may exaggerate 
or mask the true treatment effect.   One group may be merely lagging behind another in time, 
and an effect - either beneficial or otherwise - apparently associated with an intervention, CHE Discussion Paper 171  5
may be spurious.   Third, the likelihood of chance differences may be high, and groups may, 
at any time, be at different positions on a common (often cyclical) process.  Initial outliers in 
groups may be expected over time to regress to the mean, and apparent differences may 
simply reflect this underlying chance process.   The second and third kinds of bias might be 
considered special cases of selection bias in general, which in a range of guises makes the 
attribution of apparent responses to treatments or interventions problematic. [21] 
 
One partial solution to the problem of attribution caused by non-equivalence is the collection 
of additional data points at time periods before and after the intervention. [21]  A study in 
which there are only post intervention data points is potentially very misleading, as any 
contribution resulting from the intervention cannot be disentangled from what might have 
happened anyway.   Adding extra data points before and after the intervention enables some 
estimation of concurrent trends and the contribution, if any, of the intervention.    
 
The usefulness of additional data points in interpreting non-equivalent group designs is 
demonstrated by data from the study by Wagner et al (1995) [22].  The study describes the 
impact achieved on rates of surgery for benign prostatic hyperplasia in US patients by a video 
disk programme to inform patients of treatment options, (Figure 1).   Patients in the 
intervention group, Colorado, received the intervention from September 1989.   All other 
districts described in the figure served as controls.   Had data been available only from 
September 1989 onwards, we would have been unaware that the rate of change in surgery for 
Colorado was actually unchanged from the year before the intervention began, and that the 
overall rate of change for all groups was more similar than different over the study period as 
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Intervention in Colorado
Figure 1:  Surgery for Benign Prostatic Hyperplasia
Transurethral prostatectomy rates in intervention and control regions / 1000 men
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Another potential challenge to the validity of non-randomised, quasi-experimental studies is 
the contexturalising of results, limiting their generalisability to other settings.   The 
underlying principle of experimentation is that the treatment is introduced by the 
experimenter and the impact, or otherwise, is assessed.  Where treatments are allocated 
randomly, there is a strong likelihood that the treatment may be separated from its context.   
Where treatments are allocated in other ways (non randomly) this may not be the case.       
Even in randomised trials, selection bias has, for some time, been acknowledged as 
potentially important both for those receiving and providing treatment. [23]  Just as 
practitioners may be reluctant to treat patients ‘on the toss of a coin’, they may also be 
reluctant to receive interventions intended to help them provide more effective and efficient 
care on this same basis. 
 
In the example of surgery for benign prostatic hyperplasia above (Figure 1), the introduction 
of video disks may reflect existing concerns about the rate of intervention - a symptom of, 
rather than a cure for, the situation.   Another study of the impact of a mass media campaign 
explored rates of hysterectomy in the Ticino Canton in Switzerland. [24]   The campaign was 
concerned with the inappropriateness of high levels of intervention and appears to have 
arisen spontaneously through a form of media advocacy [25], rather than having been 
induced by the investigators.   The comparator, Canton Bern, was clearly not equivalent, at 
baseline, in its use of hysterectomy. Although the annual rate of hysterectomy decreased after 
the mass media campaign in Ticino, a small decrease during the year before the intervention 












Figure 2  Hysterectomy rates per 100,000 women in 2 Swiss Cantons
Intervention
1982 1983 1984 1985 1986 1987
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The neighbouring Canton, Bern, offered as a control, had experienced a fairly sharp change 
in rates between 1981 and 1982 for which no explanation is given. More fundamentally, 
concern among clinicians, leading to a change, may have been sparked by an article by a 
chief surgeon of a public hospital which itself was responsible for motivating the mass media 
campaign.  Thus, without random allocation, it is not possible to attribute cause and effect 
and the investigators’ statement that ‘there seems to be no doubt that the decrease in 
hysterectomies in Ticino was the result of the mass media information campaign’, appears 
overstated. 
 
THE UNIT OF ANALYSIS IN IMPLEMENTATION STUDIES 
 
In general, there is a natural structure to an experiment that exists quite apart from any 
treatment-related differences we may impose.  Often, this is in the form of a hierarchical 
framework, where patients are grouped together according to their family doctor, the family 
doctors by practice and the practices by health authority. Naturally, this has consequences for 
the similarities and differences we expect to see.  Patients of the same family doctor are likely 
to receive more similar treatment than patients under different family doctors: this should be 
reflected in the design and analysis of any experiment we choose to do. 
 
In many medical trials, there is an obvious ‘principal’ unit - the patient. The intervention is 
often easy to deliver reproducibly (a particular drug, say) and aimed directly at the patient, 
whose progress constitutes the outcome of the experiment. Additionally, patient to patient 
variation is usually the major extraneous source of ‘experimental error’. Here we will 
naturally analyse at the level of the patient and, in the absence of compelling reasons to the 
contrary, we shall want to randomise at the level of the patient also. In multi-centre trials, we 
may well find treatment effects varying from centre to centre, but as a rule, we shall seek to 
explain these centre-treatment interactions, rather than using them as estimates of error with a 
new unit of analysis.  However, for trials of interventions attempting to influence practice, 
there is often quite a ‘deep’ hierarchical structure with no obvious ‘principal unit’. It is this 
complexity of structure that can cause difficulty in the choice of the unit of analysis. 
 
Replication and randomisation 
As discussed in the last section, randomisation distributes potential confounding factors by 
play of chance and validates the assumptions upon which the usual statistical analysis is 
based.  Replication in an experiment serves to increase the precision of the estimates of 
treatment effects by sheer weight of numbers. Where treatment effects are expected to be 
small and the influence of other factors relatively large, substantial replication is required to 
overcome the background variation. This is why, for instance, investigators elected to 
randomise over 40,000 patients in the GUSTO trial, which compared four different 
therapeutic regimens for acute myocardial infarction. [26]  Because active treatment 
regimens were being compared and relatively small comparative effects estimated, 
substantial replication was required to achieve adequate levels of precision.  
 
Of course, in the GUSTO trial, the patients were randomised individually to the treatments 
under study, but in experiments with a hierarchical structure, such individual allocation may 
not be practicable (or even possible) and instead, treatments may be randomised to groups CHE Discussion Paper 171  9
within the hierarchy. Such allocation of groups of subjects rather than individuals is 
sometimes called ‘cluster randomisation’ and it has long been recognised that analysing such 
trials as if individuals had been allocated separately may be quite wrong. [27] 
 
Selecting an appropriate unit of analysis 
Naturally, we want a trial to provide a good estimate of the underlying population value for 
the outcome of interest and in order to achieve a sensible interpretation of the results, we 
need a measurement of the uncertainty associated with that estimate. The effect that the 
choice of unit of analysis has on our measurement of uncertainty (or ‘error’) becomes clear if 
we examine how we arrive at the latter. 
 
The error estimate comes from the data, using the differences in outcome between units that 
received the same treatment. The number of such independent comparisons is termed the 
‘residual degrees of freedom’.  Pooling the information from these gives an estimate of the 
background variance and dividing this by the replication of each treatment (degrees of 
freedom) gives estimates of the variances of the treatment means. The square roots of these - 
the standard errors - can then be used to construct confidence intervals for the treatment 
effects. When the outcome is binary - e.g. survival after six months - the error estimates are 
constructed from a theoretical model - the binomial distribution - but they can be thought of 
in the same way.   
 
In other words, the choice of unit of analysis has a critical effect upon the interpretation of 
the results of an experiment, as it determines the number of degrees of freedom on which the 
estimation of background variance is based, affecting the estimates of standard errors - and 
hence the statistical power - through two routes. 
 
Where there are several options for the unit of analysis, as is often the case in trials that aim 
to influence physician behaviour, the right approach may not be immediately apparent. There 
is no magic formula through which the correct unit of analysis may be determined, but the 
answers to four questions (Table 2) should help the process. 
 
Table 2: Questions to inform decisions on an appropriate unit of analysis 
1.  What is the unit of randomisation? 
2.  At what level is the intervention aimed (e.g. doctors, patients, 
hospitals)? 
3.  What is the main outcome being measured? 
4.  What are the major factors that affect results (other than the 
interventions themselves)?   
 
The units of randomisation, intervention and outcome measure are the important levels of an 
experiment and the factors inducing variation at each level can differ markedly in type and 
importance.  For the ‘simple medical experiment’ the answers to questions 2 to 4 all point to 
the patient being the desirable unit of analysis. If the patient is also made the unit of 
randomisation (question 1), this provides formal justification for an analysis on that basis. 
There is always a case for making the unit of analysis the same as the unit of randomisation. 
Standard errors from such an analysis are valid indications of how much the results of the Evaluating Change in Professional Behaviour  10 
experiment would be expected to change had a different randomisation been used. The use of 
a unit of analysis different from the unit of randomisation assumes that the variation 
associated with the level of randomisation is unimportant. 
 
Thus, if practices or organisational groups are randomised, one approach is to analyse the 
results of the experiments in terms of change at the level of the practice or organisational 
group. An intervention such as educational outreach [28] may influence not only physicians 
directly, but also have some sort of group effect within a practice or organisational group, 
this group effect itself varying between practices.  
 
Randomising entire practices rather than doctors within practices may also be the most 
sensible approach, for a host of sound, practical reasons.  For instance, in a study that aims to 
influence the prescribing behaviour of doctors within a practice, it may impractical to 
ascertain who actually prescribed a particular drug to a patient from computerised records or 
reimbursement data.    
 
Such a randomisation scheme (i.e. by practice) would ‘fit’ well with an analysis at the 
practice level. However, it may be equally reasonably for the investigator to suppose that any 
‘practice effect’ is small compared to the differences between doctors, as it is the doctors 
within practices who take decisions, rather than practices as a whole. This would suggest that 
it may be better to base the analysis on variability at the level of the doctor (the decision-
maker) rather than the practice. Such an approach is defensible, but only if proper 
consideration has been given to the size of any potential group (‘cluster’) effect. 
 
It has long been established that to ignore clustering can easily produce an artificially precise 
estimate of treatment effect, as the estimates of standard error then become too small, making 
estimates of treatment effects appear better than they are, and producing significant 
differences when none really exist.  For example, in a comparison of process and outcome for 
hospitalised patients treated either by family physicians or internists, Franks and Dickson 
[29] observed an apparently very strong relationship between the number of diagnoses 
assigned and the discipline of the attending doctor.  Internists assigned an average of 0.35 
additional diagnoses per patient.  When analysed using the 1988 patients as the unit of 
analysis the standard error was 0.08, and the p value < 0.0001.  However, when analysed 
(correctly) using the 78 doctors as the unit of analysis, the standard error was 0.18 and the 
reported p-value 0.05.  
 
In other words, randomisation by cluster, accompanied by an analysis appropriate to 
randomisation of individual patients, is an exercise in self-deception. [30]  Techniques are 
available to take the potential “clustering” effect into account in analyses and in the 
estimation of sample size. [28, 31-35]  These approaches calculate the effective loss of 
replication (and thus statistical power) as a consequence of cluster randomisation on the basis 
of estimates of the intra-cluster correlation coefficient, which is a measure of the variation 
between units, according to whether they belong to the same or to different clusters.  In other 
words, the intra-cluster correlation coefficient describes the extent to which subjects within a 
cluster are truly independent of each other, and to what degree their attributes may be CHE Discussion Paper 171  11
predicted from knowing to which cluster they belong. A correlation coefficient of zero 
indicates that subjects are completely independent of each other, whilst a coefficient of 1 
indicates that membership of a cluster and a particular attribute are perfectly correlated. 
 
Of course, the true intra-cluster correlation coefficient is generally unknown, and must be 
estimated from the available data. Unfortunately, statistical problems can arise if we need an 
estimate of the intra-cluster correlation coefficient when the number of clusters is small and 
in such cases, the consequent small number of degrees of freedom for error at that level may 
be inadequate for stable estimation.   
 
When we assess the level at which an intervention is targeted, it becomes clear that for 
interventions aimed at influencing physicians, conducting an analysis at the level of their 
patients is almost always likely to be inappropriate, as it provides an inadequate 
representation of variability at the level of the decision-maker. In consequence, such an 
analysis will generally give misleadingly precise estimates of treatment effects.  
 
While it makes sense to use patients or episodes of care to provide estimates of physician 
behaviour (e.g. proportion of prescriptions for drug A) and such estimates should be 
determined from sufficient numbers of patients to minimise measurement error, a single 
number applying to each physician or practice should go forward into an analysis. However, 
if there are unequal numbers of patients attached to each physician or practice, this may lead 
to errors in the unweighted point estimate of effect.   
 
Selecting the wrong unit of analysis can be seriously misleading, but as an alternative to 
attempting to select a single ‘best’ level for the analysis, it is possible to consider modelling 
the whole hierarchy using appropriate statistical techniques.  
 
Multi-level models / hierarchical models 
Recently, work on hierarchical techniques, or multi-level models –(developed particularly by 
those with an interest in education [36]) has received some interest in health services 
research. [26,27]  These approaches model the hierarchical structure of data common in 
health care. 
 
Duffy and colleagues [37] demonstrate that cluster randomisation leads to a reduction in 
statistical power, but identifying antecedence data (or predictors of outcome) for subjects 
within a cluster and including this in the analysis may substantially improve the statistical 
power of a study.  Multi-level models may make use of this phenomenon to provide estimates 
of the effects of an intervention at a higher level through the attributes of subjects at a lower 
level.  In other words, the variability between doctors’ behaviour may, in part, be explained 
by the attributes of their patients.  Multi-level modelling has been used to describe regional 
variations in mortality rates in England and Wales [38], though standard methods for multi-
level modelling are based upon nested ordinary least squares (iterative generalised least 
squares) regression models, and so are equivalent to analyses based upon the estimated intra-
cluster correlation coefficient, taking the estimated covariance structure to be true.  This 
approach may be unstable where the numbers are small at any level of the hierarchical Evaluating Change in Professional Behaviour  12 
structure. [39]   Indeed, Diwan and colleagues [40] in their simulation study of the 
implications for power in a proposed study of physicians working in health centres (which 
formed the clusters for analysis) described how an increase in the number of clusters, rather 
than an increase in the number of doctors or patients within a health centre, leads to an 
increase in statistical power.   
 
The use of standard hierarchical modelling techniques suggests a somewhat paradoxical 
situation.  The quest for additional statistical power may lead to acceptance of an approach 
that may only be stable in the large sample situation, yet in that situation, analysis at a higher 
level may already be adequate (without recourse to multi-level techniques).  Fortunately, 
hierarchical approaches have been developed based upon techniques that adequately model 
sparse data, permitting analyses that take account of the potential instability of the observed 
covariance structure. [39-41] 
 
Multi-level techniques have been developed with survey data very much in mind, and we are 
aware of no occasion when this approach has been used in an implementation trial. It is our 
intention to use these methods in the secondary analysis of an ongoing randomised trial of the 
effectiveness of educational outreach visits by community pharmacists attempting to 
influence prescribing in UK primary care.  It should be noted that this approach may lead to a 
reduction in the precision in estimates of the effects between clusters when compared with an 
analysis based upon summary data, rather than inevitably leading to greater statistical power.   
Hierarchical techniques have been used to ‘control’ for patient, diagnostic and practitioner 
variables in an analysis of prescribing data from New Zealand. [42]  Although including 
patient characteristics can improve the predictive power of a statistical model, in this instance 
it did not explain inter-practitioner variability in prescribing rates.  This conclusion is perhaps 
unsurprising in the context of intervention trials where it is doctors whose behaviour is being 
influenced. Doctors do not respond passively to variability in patients, so this may provide an 
inadequate model upon which to base our understanding of variations in practice, although 
variability in their response to different patients may in itself be of interest in health services 
research.   
 
At a practical level, rather than ‘controlling’ for differences in patient characteristics, trials 
may prove more useful if they intervene in a representative sample of practices and examine 
the extent to which certain characteristics may undermine the overall results through 
stratified randomisation or, less desirably, in pre-specified subgroups. [43] 
 
Some grey areas remain and in these instances it may be helpful to consider the outcome that 
the intervention hopes to achieve. For example, computerised decision support systems, such 
as those providing drug dosage advice, may be used to replace physician decision-making 
(and thus physician variability). Here it makes sense to analyse the experience of patients, 
because two different computers running the same software would be expected to react 
identically to the same situation. It is clear that the outcome is based at the level of the patient 
and the intervention used is intended to remove prescriber variability.  However, where the 
comparison is with ‘normal practice’, there may be differences of practical importance 
between physicians, making analysis at the level of the physician  more appropriate. CHE Discussion Paper 171  13
 Having chosen what seems likely to be the most appropriate unit of analysis, investigators 
might consider examining the robustness of their results to the assumptions made through 
sensitivity analyses. For example, analysis at the level of the doctor rather than practice could 
conceivably give answers that are qualitatively different, as well as having different levels of 
precision. Given the importance of this question, it would be helpful if published papers 
provided summary data on a range of potentially appropriate analyses, a situation uncommon 
in current practice. [44] 
 
The best time for an experimenter to think about all these issues is at the design stage of the 





Interventions aiming to help health professionals provide better health care are subject to 
variation at a number of levels, both in their analysis and subsequent application. The 
findings of implementation studies arise from particular health-care contexts (i.e. they present 
particular messages in particular settings), but may not apply well in different contexts.  If the 
message changes, will the method of behavioural change still achieve the same result?  In 
general, there are a number of issues concerning variation and bias that are particular to 
health-professional behaviour-change experiments, and these naturally lead to a discussion of 
block designs. Block designs offer not only the potential for increased precision, but also the 
ability to separate one source of variation from another. For instance, a study examining the 
impact of interventions on different topics in the same health professionals may provide 
particularly useful information on the generalisability of an intervention across topics. 
 
The Evidenced-Based OutReach (EBOR) trial, in progress at the time of writing, aims to 
evaluate the use of academic detailing in improving uptake of the findings of evidence-based 
cost-effectiveness guidelines.  General practices in six pairs of health authorities are 
randomised to receive either mailed guidelines or outreach visits in four clinical topics (See 
Figure 3).  Here, there are six ways of dividing the four topics into two ‘active’ and two 
untargeted topics (which serve as controls), and all six appear in the experiment: one in each 
of the six pairs of health authorities. 
 
Figure 3:  The EBOR study design 
 Health  Authorities 
  1 North  2 North  3 North  4 North  5 North  6 North 
  1 South  2 South  3 South  4 South  5 South  6 South 
Ace inhibitors  Outreach  Outreach  Outreach  Mail Mail Mail 
Antidepressants  Outreach Mail  Mail  Outreach  Outreach Mail 
Antiplatelet 
therapy 
Mail  Outreach Mail  Outreach Mail  Outreach 
NSAIDs Mail  Mail  Outreach Mail  Outreach  Outreach 
 
The EBOR trial is a real-world, randomised study that will provide internally and externally 
valid estimates of the effect of educational outreach visits by trained community pharmacists, 
intended to improve the quality of prescribing in English primary care.  The complex design Evaluating Change in Professional Behaviour  14 
of the study is not experienced by the individual health authorities taking part, since selected 
practices simply receive two guidelines by outreach.  The design has substantial advantages 
over a simple randomised design, since a range of guidelines are included and there is 
replication at the level of the health authority, meaning that a single authority provides only 
one-twelfth of the data for an individual guideline. 
 
Such designs are sometimes regarded as balanced, incomplete block designs (BIBD), [45] 
with ‘incompleteness’ due to the inherent impossibility of including all interventions within a 
block, rather than the undesirability of so doing. More cogently, if the topics used are 
considered representative of some larger set of candidate topics to which one would wish to 
generalise the results, it is better to regard them as a blocking factor and the plan a row and 
column design, rather than a BIBD.  
 
The Hawthorne effect, (the effect on behaviour simply as a result of involvement in a study) 
is a potential bias in studies that treat controls and active intervention groups differently. It 
has been argued that, as all subjects in a block design receive active interventions, the 
Hawthorne effect is likely to be equal for all those involved in such a study and the measure 
of the effect of the intervention will not be biased. [46]  Block designs by themselves should 
not be expected to provide a complete answer to this problem. The assumption that a 
Hawthorne effect acts in a uniform manner across all activities for the health professional (for 
active intervention topics as well as control topics) is probably unrealistic. The beneficial 
effect of being part of a trial may be larger for active topics than hidden or untargeted ones 
and it is natural to think that this will be the case if the Hawthorne effect is regarded as a 
form of placebo effect that cannot be addressed by using a placebo control (as it would be in 
a drug trial).  Further, even if the Hawthorne effect has some overall, uniform, non-specific 
effect upon study subjects, it can still interact with the intervention. The potential impact 
upon generalisability should not be ignored. [47]   In other words, the study context needs to 
be considered as part of the intervention received. It may be that effects identified in a study 
would not have occurred had the Hawthorne effect not been present, or that the Hawthorne 
effect may ameliorate the positive impact of an intervention, and effects in practice would be 
larger. Put another way, a sample that may have begun as random (of GP practices, say) and 
so generalisable to some larger population may no longer be random as soon as it becomes 
the subject of experiment, if the experiment is in some way ‘intrusive’. Thus, although it is 
possible that designs in which all subjects receive active interventions have the best chance of 
avoiding bias through Hawthorne effects, it also remains important that investigators try to 
reduce the impact of involvement in an investigation in other ways. 
 
The problem of ‘contamination’ is another concern in block designs.  By including both 
active and control interventions in the same block, there is the assumption that behavioural 
interventions have effects specific to their targeted activity, and so will not act upon non-
targeted interventions. Often this assumption will seem quite reasonable.  Taking the example 
of Norton & Dempsey (1985) described above, [48] it is assumed that audit and feedback 
targeted at the treatment of vaginitis will not impact upon the treatment of cystitis by the 
same health professional, and vice versa.  In other cases, the possibility of contamination may 
be greater. Where, for instance, the investigators are examining the impact of educational CHE Discussion Paper 171  15
outreach visits on health professionals’ uptake of guidelines, it may be that some aspects of 
the educational process will impact upon the uptake of guidelines generally, leading to 
systematic underestimation of the treatment effect.  
 
Weighing the pros and cons of block designs 
Block designs offer potential advantages in the reduction of both variance and bias, as 
discussed above, (accepting the caveat concerning contamination). They can also be made 
quite complex, simultaneously providing answers to several questions of interest within the 
same context. This may improve the generalisability of a study and also add to its ‘construct 
validity’. 
 
Block designs (in which all subjects receive an active intervention) may limit the impact of 
the Hawthorne effect, but it is sometimes possible, both ethically and practically, to conduct 
trials where subjects are totally unaware that they are part of an experiment providing a 
complete answer to the Hawthorne effect. An example is the trial by Oakeshott et al, [49] 
where 170 UK family physicians in 62 practices were randomised to receive guidelines on 
the appropriateness of requests for radiological examinations, or control. Outcome measures 
were derived from routinely collected data sources and the trial addressed the important 
question of whether or not it is worthwhile mailing guidelines to local practitioners. Although 
a block design would have been possible, where different radiological guidelines were sent to 
different groups, this would have addressed a slightly different question (specifically, the 
content of the guidelines) which may not have been the object of the research. Given the 
availability of routinely collected outcome data, the facility to run the trial in the background 
and the nature of the question addressed, in this instance, the simple design used had clear 
advantages over more complex alternatives. 
 
In general, simplicity in design will bring the advantage of a ‘light touch’ and less room for 
error. If the pertinent questions can be addressed within a simple design, the decision 
between a simple or complex design can be made merely on the grounds of which is the more 
cost-effective in gaining the desired information.  Addressing the right questions is vital, but 
it will not always be the case that complexity of design helps us do this. Whilst complex 
designs may be useful for examining the interactions between different parts of an 
intervention, they may also, by virtue of their sophistication, prove difficult to interpret. [50]  
Additionally, the artificial constraints inherent in such designs (particularly the restriction of 
the Latin square that the numbers of treatments must be equal to the numbers of rows and 
columns of the square) may  impede the optimum choice of treatments  included in the study.  
Simple designs may be useful to examine simple questions, but they may be equally good for 
rather complicated ones - an example being the influence of opinion leaders on rates of 
caesarean section in Canada. [51] 
 
AN ECONOMIC PERSPECTIVE  
 
In an earlier section, it was emphasised that groundwork in understanding the nature of an 
intervention is necessary before designing and conducting trials.  This is true not only of the 
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the necessity and achievability of a change in activity before implementation is attempted.  If 
the need for change has not been established by available evidence, then the result of an 
implementation study will be uninterpretable, reflecting both varying response to the method 
and varying scepticism about the message. 
 
Outcomes 
It is normally appropriate to use intermediate outcomes to estimate the effect of an 
implementation strategy (e.g. the proportion of patients per clinical practice for whom 
prescribed care follows guidelines recommendations). 
 An implementation study, targeted at 
changing practice in line with good evidence of effectiveness and cost-effectiveness from 
treatment trials, may permit health service decision-makers to evaluate a policy of changing 
professional behaviour by combining the implementation findings with treatment trial results 
or, if appropriate, a meta-analysis (Figure 4).  Thus the implementation trial measures the 
change in resources required by the implementation method and level of change in clinician 
behaviour achieved (∆bi, ∆ci).  These findings are combined with the health gain estimates 
and resource implications from trials, which have previously assessed treatment (∆bt, ∆ct).  
Evaluating a policy of behaviour change requires the decision-maker to include scale factors 
specific to the local context (n, the number of practices affected; N, the number of patients).   
 






∆ci: net cost of implementing
change per practice
∆bi: change in the proportion of care
following guidance, per practice
Treatment
Trial
∆ct : net cost of treatment per patient
∆bt : net health gain per patient
Estimated benefit of a policy of implementation, where
n = number of practices, and
N= number of patients covered by policy :
∆ C ≈ ∆ci.n + ∆bi.N.∆ct Net health policy cost1,2
∆ B = ∆bi.N.∆bt Net health benefit 2
1 This may serve as a useful starting point, but formally a local recosting exercise is required
2 Assuming the treatment trial has current care as a comparison to the intervention
3 Or the cost and effect of implementation may be analysed at the level of the clinician, in which case n
becomes the number of clinicians
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A common mistake made by health economists new to the field of implementation research is 
to recite the mantra that patient health outcome data should be measured: this is unlikely to 
be appropriate in implementation trials.  Appropriate statistical analysis would be complex, 
since the outcomes of groups of patients would be related where they shared the same 
clinician or practice.  Additionally, costly collection of a much larger data set would 
generally be required to record patient outcomes, as well as a larger trial of longer duration.  
For these reasons, implementation trials measuring patient health outcomes are likely to fall 
between stools, failing to reach statistical significance in health gains and confusing doctors 
as to why health outcome is being measured at all if the benefits are already proven.   
 
Where patient outcome measures are argued for, as part of the design of an implementation 
trial, this issue should be explored and if there is concern that benefits from trials may not 
translate into local practice a pragmatic treatment trial may be required instead (i.e. the 
worthwhile nature of intervention has yet to be fully established). There is a more general 
viewpoint that health outcomes should be measured routinely in clinical practice, but 
implementation trials may not be a suitable vehicle to introduce clinical audit using health 
outcomes, since the respective data requirements are quite different. 
 
The perspective of the economics of an implementation trial is legitimately narrow.  The trial 
should be adequately powered to assess clinically important levels of behaviour change and 
be set against the net cost of implementation.  The resources required to achieve change 
should be reported in detail so that decision-makers can cost implementation in their own 
locality.   
 
Choosing alternatives 
Interventions may take the form of passively disseminated printed educational materials, 
computer support systems, active implementation involving inclusion in focused educational 
events, audit cycles, discussion with a pharmacist or changes in financial incentive structures. 
Choosing relevant alternatives in trials to compare with implementation strategies requires 
care and a range of potential alternatives may be appropriate. Since it is common for there to 
be no formal implementation of specific research findings, it is generally appropriate to 
compare an implementation strategy with no formal intervention. The control group may 
receive no formal intervention, but be exposed to the same material by publication in 
professional journals (the traditional path of implementation) or may be handed the materials 
in a passive implementation as a means of evaluating the added benefits of a more active 
approach. 
 
When considering alternatives, it may be invaluable to solicit the perspective of health 
service decision-makers for their views of the relevant alternatives and to address whether 
more active and expensive implementation strategies stand any chance of being adopted. [52]  
Costs and consequences may be expected to vary substantially, depending upon the clinical 
intervention chosen, the health system being studied, and the implementation approach used.  
(Printed educational materials are relatively cheap to distribute; focused educational meetings 
are much more expensive.)  It is often difficult to transfer resources within health systems 
and changes in practice effected by guidance may have apparently perverse results that Evaluating Change in Professional Behaviour  18 
should be considered.  For example, it has been argued that reducing the level of surgery for 
otitis media with effusion in children in the UK will, overall, lead to an increase rather than a 
decrease in costs, since available theatre time may be used for interventions that are more 
resource intensive and probably equally poorly supported by the evidence. [53] 
 
Choosing a power provider 
A successful implementation trial would contain both a message to convince clinicians of the 
need for change, and achieve a level of change that managers consider worthwhile.   
However, a ‘clinically important change’ for an implementation method is not yet a well-
defined concept and requires further study.  Some of the issues for clinicians and managers 
are rehearsed here. 
 
It is uncertain how health policy decision-makers will respond to the results of 
implementation studies.  Will they be interested simply in the proportion of change achieved 
by the trial (for example: 1% change - bad, 10% change - good) conveying a ‘worthwhile’ 
message, will they respond to the overall benefit (proportion of change multiplied by health 
gain), or will the overall budgetary implications of change be most influential?  As a starting 
point for powering implementation trials, it may be appropriate to assume that decision-
makers (like clinicians) respond to relatively simple notions like ‘worthwhile’ rather than 
more complex constructs like ‘cost-effective’ or ‘efficient’.  Hence, the primary objective 
may be set by identifying the level of change in behaviour that managers perceive to be 
important enough to act upon, though there are risks in this approach.  It may be that 
relatively cheap implementation methods, achieving small changes in practice, provide the 
most cost-effective strategy to achieve worthwhile health gains, albeit remaining unattractive 
to managers.  Similarly, there may be situations where less cost-effective methods may 
achieve greater absolute changes in the treatment of patients. 
 
Design of economic aspects of implementation studies needs care, as does the presentation of 
economic messages in guidance given to clinicians. Health economists naturally equate a 
‘worthwhile’ message with ‘cost-effectiveness’, but it remains a research issue as to whether 
clinicians respond to cost-effectiveness per se or to other constructs (e.g. first: this treatment 
has important health benefits; second: I can achieve these benefits; third: the budget can 
afford it).  It may be important to consider the nature and presentation of the message in an 
implementation study with respect to the size of costs, benefits and other attributes of 
treatment, as all of these may influence the uptake of a message.   
 
For example, low-dose aspirin prophylaxis for patients with cardiovascular disease is very 
cheap and likely to be relatively cost-effective when compared with ace-inhibitors given for 
heart failure, but ace-inhibitors are likely to have substantially greater health benefits.   
Additionally, the time taken to achieve health benefits can vary considerably.  In economic 
evaluation, the traditional approach for coping with differential timing of costs and benefits is 
to discount future (quality-adjusted) survival and cost profiles.  Discounting (and the whole 
health outcome metric) may inadequately reflect clinician preference for treatments with 
relatively immediate and substantial benefits measured directly from trials of treatments, as CHE Discussion Paper 171  19
opposed to primary prevention activities with a long lead time to benefits (often) estimated 




The successful introduction of a new pharmaceutical product follows from a long and 
painstaking process with substantial attrition of ‘good ideas’ en route.  Similar rigour in 
design of implementation studies should reduce the enactment of poorly conceived, but 
expensive, studies that have skipped the preliminary stages without adequate consideration.  
Clarity on the aims of an experiment is vital in determining a sensible protocol.  Questions of 
different types can rarely be addressed efficiently in a single experiment and it is a mistake to 
try.  A structured development process is required for implementation methods, assisted by a 
sequence of different sorts of study or experiment.  The ‘explanatory/ pragmatic’ model of 
experiments is often useful as a guide in the latter stages of development, but there is no 
substitute for examining each new case as it arises, carefully defining the aims, and being 
guided by these and the practical constraints that apply. 
 
Explanatory trials take care to control or measure extraneous factors that might influence the 
treatment effect, whilst in pragmatic trials, close control is neither possible nor desirable. As 
a principle, it remains invaluable to establish that an intervention can work and to gain an 
understanding of the way it works in studies with high construct validity before attempting to 
evaluate whether it can achieve this potential in the real world. 
 
Although useful, non-equivalent group designs require more careful interpretation than 
randomised studies.   A number of potential biases have been discussed: scaling differences, 
maturational processes, cyclical effects, selection and regression to the mean.  
 
An inappropriate choice of unit of analysis in implementation studies is at best inefficient, 
and at worst deceptive. Analysing at the level of patient rather than physician is inappropriate 
wherever we are interested in physician behaviour that cannot be explained by patient 
variability; in other words, where there are likely to be important differences between 
physicians. This is not an empirical issue.  Fitting a model that ignores physician variability 
in these circumstances is akin to expecting a free lunch (and there is no such thing).  The 
appropriate unit of analysis for implementation trials is the changed behaviour achieved in 
clinicians, either individually or as a practice group. 
 
Whilst more sophisticated statistical modelling embracing several sources of variation is 
possible, a relatively straightforward analysis at the right level may well retrieve most of the 
information from the data.  Multi-level models using appropriate statistical techniques can 
have some advantages over simple analyses at the appropriate unit of analysis, especially 
where antecedence data are available that may explain some of the variability observed.   
However, more work is required, particularly in the context of controlled trials.   
 
The use of a block design in which individual practices provide data both on the effect of 
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estimates of treatment effect.  The approach also extends the scope of the evaluation from a 
single guideline topic to a range of guidelines, thus increasing the generalisability of the 
study.   
 
Implementation methods should not be considered before it has been established that a 
worthwhile treatment or health care intervention is being under-utilised.  Implementation 
trials conducted without this foundation may fail either because the method is ineffective or 
because clinicians do not accept the importance of the message.  Careful consideration is 
required in the design of these trials to ensure evaluation of the implementation method and 
avoid confounding influences. 
 
The resource consequences of the implementation method and the level of behavioural 
change achieved are being measured in an implementation trial, not the costs of treatment or 
health outcomes.  Existing evidence of the cost-effectiveness of treatment should have 
contributed to the basis for the need of an implementation strategy. With appropriate 
methodology, it appears possible to design studies which ‘bolt on’ to the treatment evidence 
and allow decision-makers to assess the value of a policy to implement change in their own 
setting.  However, whether those involved in policy and treatment decisions respond to levels 
of change in behaviour or more complex constructs of health benefits or cost-effectiveness 
resulting from change remains a research issue. 
 
Educational outreach visits by trained pharmacists are a commonly used strategy intended to 
affect prescribing practice in the UK, though to date there have been no large randomised 
trials examining the efficiency of such practices.  EBOR will provide a valid estimate of the 
effect of outreach based upon a random sample of practices. CHE Discussion Paper 171  21
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